All In Biotech

Drug Trial Radar · NCT06919003

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (RTB-021)

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

May 30, 2031

Study completion May 30, 2032

Sponsor

Sponsor type
NIH
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned. The primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)

Conditions

  • Kidney Transplant

Interventions

  • BerinertBiological

    Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft

  • Placebo for BerinertOther

    Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference between study arms in renal functionTime frame: At 12-months post-transplantation

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Kansas University Medical Center

    Kansas City, Kansas · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.